28042952|t|Uncoupling protein 2 downregulation by hypoxia through repression of peroxisome proliferator-activated receptor γ promotes chemoresistance of non-small cell lung cancer
28042952|a|Hypoxic microenvironment is critically involved in the response of non-small cell lung cancer (NSCLC) to chemotherapy, the mechanisms of which remain largely unknown. Here, we found that NSCLC patients exhibited increased chemotherapeutic resistance when complicated by chronic obstructive pulmonary disease (COPD), a critical cause of chronic hypoxemia. The downregulation of uncoupling protein 2 (UCP2), which is attributed to hypoxia-inducible factor 1 (HIF-1)-mediated suppression of the transcriptional factor peroxisome proliferator-activated receptor γ (PPARγ), was involved in NSCLC chemoresistance, and predicted a poor survival rate of patients receiving routine chemotherapy. UCP2 suppression induced reactive oxygen species production and upregulation of the ABC transporter protein ABCG2, which leads to chemoresistance by promoting drug efflux. UCP2 downregulation also altered metabolic rates as shown by elevated glucose uptake and reduced oxygen consumption. These data suggest that UCP2 is a key mediator of hypoxia -triggered chemoresistance of NSCLCs, which can be potentially targeted in clinical treatment of chemo-refractory NSCLCs.
28042952	0	20	Uncoupling protein 2	T116,T121	C0536847
28042952	21	35	downregulation	T044	C0013081
28042952	39	46	hypoxia	T046	C0242184
28042952	55	65	repression	T045	C0920533
28042952	69	113	peroxisome proliferator-activated receptor γ	T116,T192	C0166417
28042952	123	138	chemoresistance	T039	C1514892
28042952	142	168	non-small cell lung cancer	T191	C0007131
28042952	169	176	Hypoxic	T046	C0242184
28042952	177	193	microenvironment	T082	C0014406
28042952	224	232	response	T032	C0871261
28042952	236	262	non-small cell lung cancer	T191	C0007131
28042952	264	269	NSCLC	T191	C0007131
28042952	274	286	chemotherapy	T061	C3665472
28042952	292	302	mechanisms	T169	C0441712
28042952	356	361	NSCLC	T191	C0007131
28042952	362	370	patients	T101	C0030705
28042952	381	390	increased	T081	C0205217
28042952	391	418	chemotherapeutic resistance	T039	C1514892
28042952	424	435	complicated	T169	C0231242
28042952	439	476	chronic obstructive pulmonary disease	T047	C0024117
28042952	478	482	COPD	T047	C0024117
28042952	487	495	critical	T080	C1511545
28042952	496	501	cause	T169	C0015127
28042952	505	522	chronic hypoxemia	T033	C0745188
28042952	528	542	downregulation	T044	C0013081
28042952	546	566	uncoupling protein 2	T116,T121	C0536847
28042952	568	572	UCP2	T116,T121	C0536847
28042952	598	624	hypoxia-inducible factor 1	T116,T123	C0215848
28042952	626	631	HIF-1	T116,T123	C0215848
28042952	642	653	suppression	T045	C0038855
28042952	661	683	transcriptional factor	T116,T123	C0040648
28042952	684	728	peroxisome proliferator-activated receptor γ	T116,T192	C0166417
28042952	730	735	PPARγ	T116,T192	C0166417
28042952	754	759	NSCLC	T191	C0007131
28042952	760	775	chemoresistance	T039	C1514892
28042952	793	797	poor	T080	C2700379
28042952	798	811	survival rate	T081	C0038954
28042952	815	823	patients	T101	C0030705
28042952	834	841	routine	T080	C0205547
28042952	842	854	chemotherapy	T061	C3665472
28042952	856	860	UCP2	T116,T121	C0536847
28042952	861	872	suppression	T039	C1514892
28042952	873	880	induced	T169	C0205263
28042952	881	904	reactive oxygen species	T123,T196	C0162772
28042952	920	932	upregulation	T044	C0041904
28042952	940	963	ABC transporter protein	T116,T123	C0242738
28042952	964	969	ABCG2	T116,T123	C0761993
28042952	986	1001	chemoresistance	T039	C1514892
28042952	1005	1014	promoting	T052	C0033414
28042952	1015	1026	drug efflux	T044	C1512072
28042952	1028	1032	UCP2	T116,T121	C0536847
28042952	1033	1047	downregulation	T044	C0013081
28042952	1053	1060	altered	T169	C0392747
28042952	1061	1076	metabolic rates	T039	C0870882
28042952	1089	1097	elevated	T080	C3163633
28042952	1098	1112	glucose uptake	T043	C1159527
28042952	1117	1124	reduced	T080	C0392756
28042952	1125	1143	oxygen consumption	T201	C0030055
28042952	1169	1173	UCP2	T116,T121	C0536847
28042952	1195	1202	hypoxia	T046	C0242184
28042952	1214	1229	chemoresistance	T039	C1514892
28042952	1233	1239	NSCLCs	T191	C0007131
28042952	1278	1296	clinical treatment	T061	C1516635
28042952	1300	1316	chemo-refractory	T169	C0205269
28042952	1317	1323	NSCLCs	T191	C0007131